Overview
Theranostics pairs diagnostic imaging with targeted radionuclide therapy to personalize oncology care. PSMA and somatostatin receptor agents exemplify clinical impact in prostate and NETs. Multidisciplinary coordination and dosimetry are central to safe delivery.
Radiopharmacy and Logistics
Production requires radiochemistry capacity and regulatory compliance for high activity agents. Dosimetry planning and patient isolation protocols are necessary for safety. Supply chain and reimbursement affect program scale up.
Clinical Outcomes
Theranostics show promising response rates in selected tumors and enable imaging based patient selection. Post therapy imaging guides retreatment decisions and toxicity monitoring. Long term registries will define comparative effectiveness.
Future Directions
Alpha emitters and novel targets expand therapeutic options and may improve outcomes. Personalized dosimetry and combination with systemic therapies are active research areas. Infrastructure investment and training are prerequisites for program growth.